{"corpus_id":234682735,"paper_sha":"9150ec78c85474d6eb1c3f0b4417238cb3a4786c","doi":"10.7759/cureus.14479","arxiv_id":null,"pmid":33996337,"pmcid":"8120131","mag_id":null,"dblp_id":null,"acl_id":null,"title":"Determining Bone Turnover Status in Patients With Chronic Liver Disease","year":2021,"publication_date":"2021-04-01","venue":"Cureus","journal":{"name":"Cureus","pages":null,"volume":"13"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article"],"s2_fields_of_study":["Medicine"],"reference_count":23,"citation_count":5,"influential_citation_count":0,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":null,"chemicals":null,"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://www.cureus.com/articles/42980-determining-bone-turnover-status-in-patients-with-chronic-liver-disease.pdf","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/9150ec78c85474d6eb1c3f0b4417238cb3a4786c","s2_open_access_license":"CCBY","s2_open_access_status":"GOLD","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Introduction Hepatic osteodystrophy is an osteoporotic bone disease that occurs in chronic liver disease patients. The global prevalence of osteoporosis in patients with chronic liver disease is 30% to 40%. The pathogenesis of hepatic bone disease is not clear, but it occurs due to unstable bone remodeling with increased bone resorption and decreases bone formation. There has been an interest in determining the clinical utility of bone turnover markers (BTMs) in the assessment of osteoporosis in chronic liver patients. Methods This was a cross-sectional study conducted in patients with chronic liver disease at the section of chemical pathology, department of pathology and laboratory medicine, Aga Khan University (AKU). A total of 50 patients with age >8 years and a history of liver disease >6 months were recruited from January to October 2019. Liver function tests, i.e. aspartate aminotransferase (AST), alanine transaminase (ALT), albumin, and bilirubin, along with clinical signs of liver disease chronicity, were noted. The samples for BTMs, i.e. total serum alkaline phosphatase (ALP) and serum C-terminal telopeptide of type-1 collagen (CTX) were withdrawn and analyzed on Microlab (ELItech Group, Puteaux, France) and ADVIA Centaur (Siemens Diagnostics, NY), respectively. Results The majority of patients were males (n=34, 68%). Twenty-four (48%) patients suffered from fibrosis while 26 (52%) were without fibrosis. Median platelet count (68×109/L (102.5-50)) and median cholesterol levels (102.5 mg/dl (147-99.5)) were decreased, whereas gamma-glutamyl transferase (GGT) levels were higher in the fibrosis group as compared to the non-fibrosis group. The median levels of total ALP were 91.5 IU/L (103-82), and the median levels of CTX were 0.24 pg/ml (0.34-0.21). Conclusion In the present study, no significant difference was found in the BTMs of patients with and without chronic liver disease (CLD). However, there was a positive and significant correlation of BTMs, particularly CTX with age, bilirubin levels, and hepatomegaly.","claims":[{"public_id":"cl_f85b475dc5f1a6990f7b8d538b4b5854","status":"active","text":"CTX showed a positive and significant correlation with age, bilirubin levels, and hepatomegaly.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_f85b475dc5f1a6990f7b8d538b4b5854"},{"public_id":"cl_7ecfdb4798574dc51d19020020051262","status":"active","text":"Median total alkaline phosphatase and median CTX levels were 91.5 IU/L and 0.24 pg/ml, respectively, in the studied chronic liver disease cohort.","confidence":0.88,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_7ecfdb4798574dc51d19020020051262"},{"public_id":"cl_a5da603086c5a62df2e50eb472a1d969","status":"active","text":"No significant difference was found in bone turnover markers between patients with and without chronic liver disease.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_a5da603086c5a62df2e50eb472a1d969"}],"concepts":[{"public_id":"co_2a008fae79b86c00962c41a3fcdde49e","status":"active","name":"serum C-terminal telopeptide of type-1 collagen","description":"A serum marker of bone resorption measured in the study.","types":["biomarker"],"aliases":["CTX"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_2a008fae79b86c00962c41a3fcdde49e"},{"public_id":"co_409c98cd578a6e32c71b49d79ca7062c","status":"active","name":"age","description":"The patient's chronological age used in correlation analysis.","types":["clinical variable"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_409c98cd578a6e32c71b49d79ca7062c"},{"public_id":"co_65484af5a8130540cf6fb669d3357e33","status":"active","name":"chronic liver disease","description":"A long-standing liver disorder affecting patients enrolled in the study.","types":["condition"],"aliases":["CLD"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_65484af5a8130540cf6fb669d3357e33"},{"public_id":"co_81a19f5d5c627dca1b10f44587359bdf","status":"active","name":"hepatomegaly","description":"Enlargement of the liver recorded as a clinical sign of liver disease chronicity.","types":["clinical sign"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_81a19f5d5c627dca1b10f44587359bdf"},{"public_id":"co_92a1448d0b7115fc6c6b704c1c173338","status":"active","name":"chronic liver disease cohort","description":"The group of 50 patients with chronic liver disease analyzed in the cross-sectional study.","types":["study cohort"],"aliases":["studied cohort"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_92a1448d0b7115fc6c6b704c1c173338"},{"public_id":"co_b6f1342c71b2e3092e2a7978b244c181","status":"active","name":"bone turnover markers","description":"Laboratory markers used to assess bone formation and bone resorption activity.","types":["measurement category"],"aliases":["BTMs"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b6f1342c71b2e3092e2a7978b244c181"},{"public_id":"co_d2e562ba05552090f1e48cc0caaffb76","status":"active","name":"total serum alkaline phosphatase","description":"A serum enzyme measure used here as a bone turnover marker.","types":["biomarker"],"aliases":["ALP"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_d2e562ba05552090f1e48cc0caaffb76"},{"public_id":"co_d70963c60a24b3d3be0170cc2c6bdc43","status":"active","name":"bilirubin levels","description":"Measured blood bilirubin concentrations used as a liver-related clinical variable.","types":["laboratory measure"],"aliases":["bilirubin"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_d70963c60a24b3d3be0170cc2c6bdc43"}],"external_ids":{"DOI":"10.7759/cureus.14479","ArXiv":null,"PubMed":33996337,"PubMedCentral":"8120131","MAG":null,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://www.cureus.com/articles/42980-determining-bone-turnover-status-in-patients-with-chronic-liver-disease.pdf","landing_url":"https://www.semanticscholar.org/paper/9150ec78c85474d6eb1c3f0b4417238cb3a4786c","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBY","status":"GOLD","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":632043,"paper_uid":"fa6e2403-f4d3-45fa-b849-25ef636d04cf","canonical_identity":{"paper_id":632043,"paper_uid":"fa6e2403-f4d3-45fa-b849-25ef636d04cf","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/234682735"}